Human Chorionic Gonadotropin Regression Curves after Partial or Complete Molar Pregnancy in Flanders: Are They Different from Regression Curves from the Eighties?
[en] [en] BACKGROUND/AIMS: We updated human chorionic gonadotropin (hCG) regression curves created in the eighties after evacuation of complete and partial molar (CM and PM, respectively) pregnancies using modern hCG assays. We created similar curves for patients in need of chemotherapy (gestational trophoblastic neoplasia [GTN]).
METHODS: A total of 126 patients who were diagnosed with gestational trophoblastic disease from 1990 to 2014 were included. We compared curves from 2 groups, CM and PM, with historical ones. The third group was a comparison of GTN patients receiving first-line chemotherapy and patients in need of a switch of chemotherapy.
RESULTS: The regression curves were comparable to historical ones. According to the latter, mean time to normalization was 14-15 weeks after evacuation. We observed a normalization within 12 (CM) and 12.7 (PM) weeks. In addition, a remarkable but not statistically significant vertical shift (20 IU/L higher) was observed prior to day 60 compared with historical curves. The comparison in GTN patients showed a statistical significant difference, even at day 7.
CONCLUSION: The presented hCG regression curves in the Flemish region were comparable with the ones of the eighties but with a vertical shift, hypothetically due to more sensitive assays. In addition, regression curves in GTN patients receiving chemotherapy can be used to evaluate response.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Delattre, Sien; Department of Obstetrics and Gynaecology, University Hospital, UZ Leuven, Leuven, Belgium
Han, Sileny; Department of Obstetrics and Gynaecology, Leuven, Belgium
Moerman, Philippe; Department of Pathology, Belgium
Billen, Jaak; Department of Laboratory Medicine, University Hospital, Leuven, Belgium
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR)
Scharpé, Kathleen; Department of Obstetrics and Gynaecology, AZ Sint-Blasius Te Dendermonde, Belgium
Vergote, Ignace; Department of Obstetrics and Gynaecology, Leuven, Belgium
Language :
English
Title :
Human Chorionic Gonadotropin Regression Curves after Partial or Complete Molar Pregnancy in Flanders: Are They Different from Regression Curves from the Eighties?
Lurain JR: Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 2010;203:531-539.
Lurain JR: Gestational trophoblastic disease II: Classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol 2011;204:11-18.
May T, Goldstein DP, Berkowitz RS: Current chemotherapeutic management of patients with gestational trophoblastic neoplasia. Chemother Res Pract 2011;2011:806256.
Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging 2013;40:505-513.
Sebire NJ, Lindsay I, Fisher RA: Recent advances in gestational trophoblastic neoplasia. Curr Diagn Pathol 2007;13:210-221.
Buza N, Hui P: Gestational trophoblastic disease: Histopathological diagnosis in the molecular era. Dagn Histopathol 2010;16:526-537.
Hoffner L, Surti U: The genetics of gestational trophoblastic disease: A rare complication of pregnancy. Cancer Genet 2012;205:63-77.
Shih IeM, Kurman RJ: Molecular basis of gestational trophoblastic disease. Curr Mol Med 2002;2:1-12.
Hui P, Martel M, Parkash V: Gestational trophoblastic diseases: Recent advances in histopathologic diagnosis and related genetic aspects. Adv Anat Pathol 2005;12:116-125.
Chew SH, Perlman EJ, Williams R, et al. Morphology and DNA content analysis in the evaluation of first trimester placentas for partial hydatidiform mole (PHM). Hum Pathol 2000;31:914-924.
Schlaerth JB, Morrow CP, Kletzky OA, et al. Prognostic characteristics of serum human chorionic gonadotropin titer regression following molar pregnancy. Obstet Gynecol 1981;58:478-482.
Behtash N, Ghaemmaghami F, Honar H, et al. Is normal beta-hCG regression curve helpful in the diagnosis of persistent trophoblastic disease. Int J Gynecol Cancer 2004;14:980-983.
Schoeberl MR: A model for the behavior of beta-hCG after evacuation of hydatidiform moles. Gynecol Oncol 2007;105:776-779.
Matsui H, Kihara M, Usui H, et al. Comparison of 2 commercially available human chorionic gonadotropin immunoassays used in the management of gestational trophoblastic neoplasia. J Reprod Med 2009;54:631-635.
Shi Z, Zhang T, Long W, et al. Down-regulation of poly(rC)-binding protein 1 correlates with the malignant transformation of hydatidiform moles. Int J Gynecol Cancer 2012;22:1125-1129.
'hCG + Beta' of Roche Diagnostics (on Modular E 170), Basel, Switzerland.
van Cromvoirt SM, et al. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve. Gynecol Oncol 2014;133:542-545.
Lybol C, Sweep FC, et al. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer 2013;23:1150-1156.
Cole LA, Butler S: Detection of hCG in trophoblastic disease. The USA hCG reference service experience. J Reprod Med 2002;47:433-444.
van Trommel NE, Massuger LF, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J Clin Oncol 2006;24:52-58.
